-
公开(公告)号:WO2016183120A8
公开(公告)日:2016-12-15
申请号:PCT/US2016031713
申请日:2016-05-11
Applicant: VERTEX PHARMA
Inventor: FARMER LUC J , BOYD MICHAEL JOHN , SHANNON DEAN , WALDO MICHAEL , NTI-ADDAE KWAME W , ZHANG YUEGANG
IPC: C07D471/04 , A61K31/506 , A61P31/16
CPC classification number: C07D471/04
Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula, include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
Abstract translation: 其中化合物(1)由以下结构式表示的化合物(1)或其药学上可接受的盐的多晶型包括化合物(1)的水合物2,化合物(1)的水合物3,化合物(1)的晶型A ),化合物(1)的形式B,化合物(1)的形式C,化合物(1)的形式D和无定形化合物(1)。 这样的多晶型形式可用于治疗流感,抑制流感病毒的复制或减少生物样品或受试者中流感病毒的量。
-
公开(公告)号:WO2009045992A2
公开(公告)日:2009-04-09
申请号:PCT/US2008078239
申请日:2008-09-30
Applicant: VERTEX PHARMA , LAUFFER DAVID , LI PAN , WAAL NATHAN , MCGINTY KIRA , TANG QING , RONKIN STEVEN , FARMER LUC , SHANNON DEAN , JACOBS DYLAN
Inventor: LAUFFER DAVID , LI PAN , WAAL NATHAN , MCGINTY KIRA , TANG QING , RONKIN STEVEN , FARMER LUC , SHANNON DEAN , JACOBS DYLAN
IPC: A61K31/4439
CPC classification number: C07D401/14 , C07D409/14 , C07D417/14
Abstract: The present invention relates to compounds of formula I useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative disorders. Formula (I).
Abstract translation: 本发明涉及用于抑制c-Met蛋白激酶的式I化合物。 本发明还提供了包含本发明化合物的药学上可接受的组合物以及使用该组合物治疗增殖性疾病的方法。 公式(I)。
-
公开(公告)号:EP3294735A1
公开(公告)日:2018-03-21
申请号:EP16725672
申请日:2016-05-11
Applicant: VERTEX PHARMA
Inventor: FARMER LUC J , BOYD MICHAEL JOHN , SHANNON DEAN , WALDO MICHAEL , NTI ADDAE KWARNE W , ZHANG YUEGANG
IPC: C07D471/04 , A61K31/506 , A61P31/16
CPC classification number: C07D471/04 , A61K31/4965 , A61K31/506 , A61K45/06 , C07B2200/13
Abstract: include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
-
公开(公告)号:MA42422A
公开(公告)日:2018-05-23
申请号:MA42422
申请日:2016-05-11
Applicant: VERTEX PHARMA
Inventor: BOYD MICHAEL JOHN , FARMER LUC J , NTI-ADDAE KWARNE W , SHANNON DEAN , WALDO MICHAEL , ZHANG YUEGANG
IPC: A61K31/506 , A61P31/16 , C07D471/04
-
公开(公告)号:AU2009316756B2
公开(公告)日:2016-02-25
申请号:AU2009316756
申请日:2009-11-18
Applicant: VERTEX PHARMA
Inventor: LAUFFER DAVID , LI PAN , SHANNON DEAN , LIANG JIANGLIN
IPC: C07D513/04 , A61K31/433
Abstract: The present invention relates to compound (1), which is useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising Compound (1) and methods of using the compositions in the treatment of proliferative disorders.
-
公开(公告)号:ES2526902T3
公开(公告)日:2015-01-16
申请号:ES12708416
申请日:2012-01-13
Applicant: VERTEX PHARMA
Inventor: SHANNON DEAN , WANG TIANSHENG , GIROUX SIMON
IPC: C07D405/10 , C07D405/14
Abstract: Un método para preparar un compuesto de fórmula (I)**Fórmula** o una sal farmacéuticamente aceptable de este, don de R es H o F; y cada uno de los componentes R3, R4 y R5 es independientemente un grupo hidroxilo protegido opcionalmente o un alquilo sustituido opcionalmente; que comprende proporcionar un compuesto fenilpirimidínico de fórmula (II)**Fórmula** donde R es H o F, y cada uno de los componentes R3, R4 y R5 es independientemente un grupo hidroxilo protegido opcionalmente o un alquilo sustituido opcionalmente; y hacer reaccionar el compuesto fenilpirimidínico de fórmula (II) con un derivado de urea de fórmula A o B:**Fórmula**
-
公开(公告)号:ZA201305231B
公开(公告)日:2014-11-26
申请号:ZA201305231
申请日:2013-07-11
Applicant: VERTEX PHARMA
Inventor: SHANNON DEAN , LUISI BRIAN , KRAWIEC MARUISZ , KULDIPKUMAR ANUJ K
IPC: C07D20060101 , A61K20060101 , A61P20060101
Abstract: The present application is directed to solid forms of compounds of formula I: and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infections.
-
公开(公告)号:MX2013008164A
公开(公告)日:2013-08-27
申请号:MX2013008164
申请日:2012-01-13
Applicant: VERTEX PHARMA
Inventor: WANG TIANSHENG , GIROUX SIMON , SHANNON DEAN
IPC: C07D405/10 , C07D405/14
Abstract: La presente solicitud se dirige a compuestos, intermediarios y métodos para preparar compuestos de la fórmula (I) (Ver Formula) o las sales farmacéuticamente aceptables de los mismos, en donde R es H o F, y cada uno de R3, R4, y R5 son como se definen en la presente. Los compuestos de la fórmula (I) y composiciones farmacéuticas que comprenden los compuestos y las sales inhiben la girasa y/o Topo IV bacteriana y son útiles al tratar infecciones bacterianas.
-
公开(公告)号:MX2013008161A
公开(公告)日:2013-08-27
申请号:MX2013008161
申请日:2012-01-13
Applicant: VERTEX PHARMA
Inventor: KRAWIEC MARIUSZ , LUISI BRIAN , SHANNON DEAN , KULDIPKUMAR ANUJ K
IPC: C07D413/14 , A61K31/4184 , A61P31/00
Abstract: La presente solicitud se dirige a formas sólidas de compuestos de la fórmula (I) y sales farmacéuticamente aceptables de la misma, que inhiben la girasa y/o Topo IV bacterianas y composiciones farmacéuticas que comprende los compuestos y sales. Estos compuestos y sales son útiles en el tratamiento de infecciones bacterianas.
-
公开(公告)号:NZ592825A
公开(公告)日:2013-01-25
申请号:NZ59282509
申请日:2009-11-18
Applicant: VERTEX PHARMA
Inventor: LAUFFER DAVID , LI PAN , SHANNON DEAN , LIANG JIANGLIN
IPC: C07D513/04 , A61K31/433
Abstract: 592825 Disclosed is 6-((S)-I-(6-(I-methyl-IH-pyrazol-4-yl)-[1,2,4]triazolo[3,4-b ][1,3,4]thiadiazol-3-yl)ethyl)quinoline (compound 1). Aldo disclosed are compositions comprising compound 1 and the use of compound 1 for the manufacture of a medicament for treating or lessening the severity of a proliferative disorder in a patient, in particular glioblastoma; a gastric carcinoma; or a cancer selected from colon, breast, prostate, brain, liver, pancreatic or lung cancer.
-
-
-
-
-
-
-
-
-